• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Be Biopharma

Be Biopharma

Advancing our science with bold humanity

  • Investors & Media
    • News Releases
    • Publications & Presentations
  • Careers
  • Contact Us
  • Search
  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
Home/Investors & Media/News Releases

News Releases

April 28, 2025

Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Read More about Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

March 3, 2025

Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer

Read More about Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer

February 6, 2025

Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates

Read More about Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates

January 15, 2025

Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company

Read More about Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company

January 7, 2025

Be Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Read More about Be Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 8, 2024

Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024

Read More about Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024

November 5, 2024

Be Biopharma Announces Upcoming Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Read More about Be Biopharma Announces Upcoming Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

October 22, 2024

Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company

Read More about Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company

September 30, 2024

Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia

Read More about Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia

June 4, 2024

FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B

Read More about FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B

May 28, 2024

Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B

Read More about Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B

May 21, 2024

Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon

Read More about Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon

May 10, 2024

Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia

Read More about Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia

April 23, 2024

Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Read More about Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

February 1, 2024

Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024

Read More about Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024

January 25, 2024

Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies

Read More about Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies

January 4, 2024

Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization

Read More about Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization

December 28, 2023

Be Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Read More about Be Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 10, 2023

Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​

Read More about Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​

November 22, 2023

Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference

Read More about Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference

November 2, 2023

Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX

Read More about Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX

October 31, 2023

Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics

Read More about Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics

October 25, 2023

Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning

Read More about Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning

October 11, 2023

Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa

Read More about Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa

May 25, 2023

Be Biopharma to Present at the Jefferies Healthcare Conference

Read More about Be Biopharma to Present at the Jefferies Healthcare Conference

May 19, 2023

Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems

Read More about Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems

May 18, 2023

Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting

Read More about Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting

May 2, 2023

Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting

Read More about Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting

December 8, 2022

Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer

Read More about Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer

May 19, 2022

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

Read More about Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

April 14, 2022

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

Read More about Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

December 16, 2021

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

Read More about Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

August 11, 2021

Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

Read More about Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

March 16, 2021

Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

Read More about Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

October 22, 2020

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Read More about Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Endpoints News|May 28, 2024

Second engineered B cell therapy enters the clinic, promising to do in hemophilia B what gene therapies can’t

Read More about Second engineered B cell therapy enters the clinic, promising to do in hemophilia B what gene therapies can’t

The Long Run with Luke Timmerman|February 14, 2023

Engineered B Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run

Read More about Engineered B Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run

Pharmaceutical Technology|May 20, 2022

Be Bio, Resilience to manufacture engineered B cells for rare diseases

Read More about Be Bio, Resilience to manufacture engineered B cells for rare diseases

Endpoints News|May 19, 2022

Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul

Read More about Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul

Biocentury|April 14, 2022

B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Read More about B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Boston Business Journal|April 14, 2022

Arch leads $130M round for cell therapy startup targeting cancer, rare disease

Read More about Arch leads $130M round for cell therapy startup targeting cancer, rare disease

Endpoints News|April 14, 2022

ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer

Read More about ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer

Fierce Biotech|April 14, 2022

Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’

Read More about Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’

Endpoints News|October 22, 2020

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

Read More about Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

FierceBiotech|October 22, 2020

Be Biopharma debuts with $52M to advance engineered B-cell therapies

Read More about Be Biopharma debuts with $52M to advance engineered B-cell therapies

Boston Business Journal|October 22, 2020

Longwood, Atlas Venture inject $52M into cell therapy startup

Read More about Longwood, Atlas Venture inject $52M into cell therapy startup

Media Contact

media@be.bio

Meet the people behind the headlines

Be Bio Team

Footer

Be Biopharma
LinkedIn X

info@be.bio

Contact Us

Careers

  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
  • Investors & Media
    • News Releases
    • Publications & Presentations

©2023, Be Biopharma

Privacy Policy

logo
  • Our Company
    • About Be Bio
    • Life at Be Bio
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Our Science
    • About BCMs
    • Our Platform
    • Publications & Presentations
  • Patients & Caregivers
  • Investors & Media
    • News Releases
    • Publications & Presentations
  • Careers
  • Contact Us